Table I.
Cohort Characteristics
| Variable* | All (n=365) |
No Recur (n=239)† |
Recur (n=105) |
Alive (n=195) |
Death (n=170) |
|---|---|---|---|---|---|
| Age (years) | 67.2 (11.0) | 67.4 (10.5) | 67.4 (10.5) | 66.0 (10.6) | 68.8 (11.4)§ |
| Gender (% male) | 167 (46) | 102 (43) | 50 (48) | 80 (40) | 86 (51) |
| Race | |||||
| Caucasian | 226 (62) | 150 (63) | 60 (25) | 107 (55) | 119 (70)§ |
| Asian | 58 (16) | 33 (14) | 22 (9) | 39 (20) | 19 (11) |
| Black | 11 (3) | 14 (6) | 9 (4) | 8 (4) | 3 (2) |
| Other | 70 (19) | 42 (18) | 13 (5) | 41 (21) | 29 (17) |
| Smoking Status‡ | |||||
| Never | 78 (21) | 44 (18) | 28 (27) | 52 (27) | 26 (15) |
| Ever | 169 (46) | 113 (47) | 48(46) | 90 (46) | 79 (46) |
| Current | 78 (21) | 82 (34) | 18 (17) | 36 (18) | 42 (25) |
| Unknown | 40 (11) | 26 (11) | 11 (10) | 17 (9) | 23 (14) |
| Additional Therapy | |||||
| Neo-adjuvant | 27 (7) | 14 (6) | 11 (10)§ | 12 (6) | 15 (9) |
| Adjuvant | 68 (19) | 28 (12) | 38 (36) | 30 (15) | 38 (5) |
| Neither/unknown | 270 (74) | 197 (82) | 56 (53) | 153 (78) | 117 (7) |
| Tumor diameter (cm) | 3.5 (2.0) | 3.3 (1.9) | 3.7 (2.8) | 2.9 (1.5) | 4.1 (2.2) |
| Stage (AJCC 7th ed.) | |||||
| I–II | 304 (83) | 211 (88) | 81 (77)§ | 179 (92) | 125 (74)§ |
| III–IV | 61 (17) | 28 (12) | 24 (23) | 16 (8) | 45 (26) |
| Histology | |||||
| Adenocarcinoma | 265 (73) | 172 (72) | 79 (75) | 142 (73) | 123 (72) |
| Squamous | 68 (19) | 47 (20) | 15 (14) | 37 (19) | 31 (18) |
| Other NSCLC | 33 (9) | 20 (8) | 11 (11) | 16 (8) | 16 (9) |
| Grade (n = 343) | |||||
| Low | 59 (17) | 44 (18) | 14 (13) | 39 (20) | 20 (12) |
| Moderate | 177 (52) | 68 (28) | 53 (50) | 51 (26) | 84 (49) |
| High | 107 (31) | 115 (48) | 31 (30) | 93 (48) | 56 (34) |
| Time to PET (days)¶ | 51 (88) | 54 (114) | 46 (36) | 47 (105) | 52 (47) |
| SUVmax (n = 88) | 8.3 (6.6) | 7.6 (6.3) | 10.2 (8.2) | 7.4 (6.3) | 9.8 (7.0) |
| SUVmean (n = 69) | 3.7 (2.4) | 6.5 (6.5) | 11.3 (9.0)§ | 3.4 (2.4) | 4.3 (2.4) |
| SUVmax (>2.5) | 16/94 (17) | 50/65 (77) | 22/22 (100)§ | 44/58 (76) | 34/36 (94)§ |
| NF-κB expression | |||||
| Low | 147 (40) | 95 (40) | 46 (44) | 80 (41) | 77 (45) |
| Moderate | 151 (41) | 101 (42) | 38 (36) | 74 (38) | 67 (39) |
| High | 47 (13) | 31 (13) | 14 (13) | 28 (14) | 19 (11) |
| Not Interpretable | 20 (5) | 12 (5) | 7 (7) | 13 (7) | 7 (4) |
| LDHA expression | |||||
| Low | 114 | 76 (32) | 33 (31) | 61 (31) | 53 (31) |
| Moderate | 153 | 108 (45) | 34 (32) | 83 (43) | 70 (41) |
| High | 85 | 45 (19) | 35 (33) | 41 (21) | 44 (26) |
| Not Interpretable | 13 | 10 (4) | 3 (3) | 10 (5) | 3 (2) |
AJCC = American Joint Committee on Cancer.
*
Standard deviation and percent shown for continuous or categorical variables respectively.
†
Excluding post-operative deaths and advanced disease at diagnosis.
‡
See methods for category definitions.
¶
From PET scan to operation.
§
Differences by p-value < 0.05.